Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 41: EUROPA-Studie - Subgruppenanalyse Abb. 42: EUROPA-Studie - Subgruppenanalyse Abb. 43: EUROPA-Studie - Sekundäre Endpunkte Aktuelles Bild - Abb. 44: EUROPA-Studie - Myokardinfarkt Abb. 45: EUROPA-Studie - Hospitalisierung Abb. 46: EUROPA-Studie - Blutdruck Abb. 47: EUROPA-Studie - Compliance Zum letzten Bild
Abbildung 44: EUROPA-Studie - Myokardinfarkt
Perindopril 8 mg once daily reduced myocardial infarction (fatal or non-fatal) by 24 % (p < 0.001). This is one of the most impressive results as curves separated early and there was a tendency for the gap between curves to widen more in time even after the end of the study follow up. As Dr Harvey White, from Cardiology Dept. Green Lane hospital, NZ commented in the EUROPA editorial: "Although the blood pressure reduction in EUROPA was small (5 mm Hg systolic and 2 mm Hg diastolic), the systolic pressure reduction might be expected to translate into a 10 % reduction in myocardial infarction, whereas the actual reduction in non-fatal MI was 24 %". This demonstrates that BP reduction should not be the predominant mechanism of benefit with perindopril.
 
EUROPA-Studie - Myokardinfarkt
Vorheriges Bild Nächstes Bild   


Abbildung 44: EUROPA-Studie - Myokardinfarkt
Perindopril 8 mg once daily reduced myocardial infarction (fatal or non-fatal) by 24 % (p < 0.001). This is one of the most impressive results as curves separated early and there was a tendency for the gap between curves to widen more in time even after the end of the study follow up. As Dr Harvey White, from Cardiology Dept. Green Lane hospital, NZ commented in the EUROPA editorial: "Although the blood pressure reduction in EUROPA was small (5 mm Hg systolic and 2 mm Hg diastolic), the systolic pressure reduction might be expected to translate into a 10 % reduction in myocardial infarction, whereas the actual reduction in non-fatal MI was 24 %". This demonstrates that BP reduction should not be the predominant mechanism of benefit with perindopril.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung